



NEWS RELEASE



For Immediate Release

D-EYE Srl Names Galileo Diagnostics, commercial branch of Genclis SA, international distributor for Veterinary Market

In a strategic agreement, Genclis' veterinary medicine branch, Galileo Diagnostics, will distribute the innovative D-EYE Portable Retinal Imaging System

Nancy, France; Padova, Italy; Pasadena, CA, USA – March 17, 2015 – D-EYE, a leading developer of advanced devices for mass health screenings and data analytics, and Genclis, a molecular diagnostic company based in Nancy, France, announced today their strategic partnership for the international distribution (excluding North and South America) of D-EYE products for the veterinary medicine market.

Genclis' commercial branch, Galileo Diagnostics, will distribute the innovative D-EYE Portable Retinal Imaging System. The advanced, affordable retinal examiner, is a phone-case-sized add-on that turns an iPhone or Android smartphone into a fundus camera capable of taking high-definition video and still images of the eye for screening and evaluating the vision health of pets, small animals, horses, birds and other species.

"Galileo Diagnostics is one of the most active and respected distributors of animal health care products in Europe, the Middle East, Asia and Africa," said D-EYE CEO Richard Sill. "Their visibility and renown within the international veterinary medical market will serve us well as we seek to introduce the benefits of the groundbreaking D-EYE Portable Retinal Imaging System to veterinarians, animal hospitals and specialty clinics around the world."

The only truly portable ophthalmoscope capable of digitally imaging the fundus of the eye, the low-cost D-EYE device simply attaches to a smartphone (Apple iOS or Android), positioned over the phone's camera lens and LED light source, enabling the phone to capture high-definition video and still images of the interior of the eye. A D-EYE software app installed on the smartphone provides step-by-step instructions and archives all examinations on a patient chart for convenient file management.

"The D-EYE product offers veterinary doctors a remarkably affordable, portable and easy-to-use tool to examine the retina," according to Pascale Bihain, Executive Vice-President, Galileo Diagnostics by Genclis. "We are excited to be working with the D-EYE team to bring this new technology to the international animal care market. Working with leading veterinary ophthalmologists, we have confirmed the product's effectiveness on dogs, cats, rabbits, and other pets and small animals, as well as horses. D-EYE has the potential to revolutionize how vets screen for disorders and diseases of the eye."

For more information about availability of the D-EYE Portable Retinal Imaging System, please contact Galileo Diagnostics at + 33 3 83 67 82 17.

About Galileo Diagnostics:

Galileo Diagnostics, a brand of Genclis SA, designs, develops and markets a complete range of solutions for veterinary allergies and other veterinary health conditions, providing ready-to-use, high-reliability products for the diagnosis and treatment of pets and other animals. Galileo's lead proprietary products are CynoDial and FeliDial, two breakthrough innovations that help veterinarians to find solutions for animals with severe symptoms of food allergies. Galileo also distributes third-party products, notably innovative connected devices. For more information on Galileo Diagnostics, please visit www.galileodiagnosics.com or call (in France) +33 6 89 26 58 97, +33 3 83 67 82 17, or +33 3 83 57 46 51 (fax).

About Genclis:

Genclis is a molecular diagnostic company in the fields of allergy and cancer. Started in 2004, the Company initiated the commercialization of its allergy molecular diagnostic tests in 2014. In the field of cancer diagnostics, Genclis based its development on the concept of DNA/RNA divergences due to transcription infidelity, an original, proprietary disruptive science. This science has already led to encouraging results in the severity prognostic of triple negative breast cancer ("TNBC"), a severe form of breast cancer. Genclis intends to rapidly impose its solution, Severidia©, as a standard for oncologists to offer their patients alternative treatment and monitoring options. Based in Nancy and Paris, Genclis had 45 employees as of February 1, 2015. Please visit: www.genclis.com.

About D-EYE

Founded in 2014, with offices in Padova, Italy, Pasadena, CA, and Boston, MA, D-EYE Srl offers a "digital eye" into the state of the human body. We design and manufacture mobile sensing and examination devices, along with companion applications, that enable mass health screenings and data collection to improve access to vital health examination services. We also develop and operate cloud-based Platform-as-a-Service (PaaS) systems that enable telehealth applications by aggregating health screening data. Our first product, the revolutionary D-EYE Portable Retinal Imaging System, focuses on eye care; subsequent mobile-health products and services will target screening and evaluation of other medical conditions and pathologies. D-EYE was developed by Si14 SpA, a visionary original design and development laboratory for novel technology products that enhance the way we live, work and play. For more information, please visit www.d-eyecare.com or call 01-626-497-9212 (US) or +39 049 7811 860 (Italy).

#